Beijing Biostar Pharmaceuticals (2563) released a supplemental announcement related to its 2024 Annual Report, published on 24 July 2025. This update focuses on the company’s employee incentive schemes, detailing granted awards for directors and employee participants across Zhuhai Huajin, Zhuhai Huaxin, and Zhuhai Huarong. As of 31 December 2024, multiple awards remain outstanding at exercise prices ranging from HK$0.1 to HK$5.0, subject to either a 12-month vesting timeline or specified performance requirements. Several participants, including certain directors and employees, have started their unlocking period, though unlocking applications or conditions are still in process for some.

The announcement also addresses potential conflicts of interest between the Single Largest Group of Shareholders and the company. According to the information provided, the board has implemented various measures in line with the Articles of Association, the Listing Rules, and other internal regulations. These include granting independent non-executive directors equal access to relevant information, requiring their prior approval for significant connected transactions, and enabling them to engage independent financial advisers where necessary. The directors have confirmed that the related party transactions carried out during the reporting period were conducted under normal commercial terms, free from any arrangement detrimental to minority shareholders.

The company’s independent non-executive directors completed a review of the 2024 related party transactions and deemed them consistent with the normal scope of operations, fairly priced, and in the overall interests of all shareholders. The supplemental announcement concludes that, barring disclosed items, there are no further matters involving conflicts of interest between the group and its Single Largest Group of Shareholders.